Seattle-based biotechnology company Adaptive Biotechnologies Corporation, listed on the Nasdaq as ADPT, is focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating disease. The company recently announced that it will hold a business update conference call and webcast after the market close on April 2, 2024. The event will begin at 1:30 PM PT / 4:30 PM ET and will be available through the Investors section of their website at www.adaptivebiotech.com.

Adaptive Biotechnologies believes that the adaptive immune system can be a powerful tool for diagnosing and treating disease, but its complexity has limited its full utilization. Their immune medicine platform aims to decode and exploit the genetics of the adaptive immune system with scale, precision and speed. The company collaborates with biopharmaceutical companies, informs drug development and develops clinical diagnostics in two main areas: minimal residual disease (MRD) and immune medicine. Their products and clinical systems focus on diagnosing, monitoring and treating diseases such as cancer, autoimmune disorders and infectious diseases, with the goal of creating personalized immune-driven clinical products for each patient.

For investors interested in Adaptive Biotechnologies, the company’s Vice President of Investor Relations, Karina Calzadilla, can be reached at 201-396-1687 or investors@adaptivebiotech.com. For media inquiries, Associate Director of Corporate Communications Erica Jones can be reached at 206-279-2423 or media@adaptivebiotech.com.

By Samantha Johnson

As a dedicated content writer at newspuk.com, I immerse myself in the art of storytelling through words. With a keen eye for detail and a passion for crafting engaging narratives, I strive to captivate our audience with each piece I create. Whether I'm covering breaking news, delving into feature articles, or exploring thought-provoking editorials, my goal remains constant: to inform, entertain, and inspire through the power of writing. Join me on this journalistic journey as we navigate through the ever-evolving media landscape together.

Leave a Reply